EntryPoint Capital’s Fulcrum Therapeutics FULC Stock Holding History

EntryPoint Capital’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$795K	Buy	217,199 +171,951	+380%	+$1.05M	0.19%	143
2026 Q1	$347K	Buy	45,248 +30,172	+200%	+$280K	0.1%	405
2025 Q4	$171K	Buy	+15,076	New	+$153K	0.07%	576

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EntryPoint Capital's FULC Position: Q2 2026 in Review

EntryPoint Capital increased its Fulcrum Therapeutics (FULC) stake by 380% in Q2 2026, buying an estimated $1.05M and bringing the position to 217,199 shares worth $795K. The position accounts for 0.19% of the portfolio, ranked #143.

EntryPoint Capital first reported a position in FULC in Q4 2025 and has held it in 3 quarters since. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

EntryPoint Capital held 217,199 shares of Fulcrum Therapeutics worth $795K as of Q2 2026.
EntryPoint Capital bought 171,951 Fulcrum Therapeutics shares in Q2 2026, an estimated $1.05M.
Fulcrum Therapeutics made up 0.19% of EntryPoint Capital's portfolio in Q2 2026, its #143 holding.
EntryPoint Capital first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 3 quarters since.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.